Ichi chinyorwa chichakubatsira iwe kusarudza kuti ndeupi waunonyatsokodzera nekupindura mibvunzo inotevera:
1.Ndeupi musiyano uripo pakati petirzepatide uye retatrutide?
2. Ndezvipi zvinobatsira zvetirzepatide?
3.Ndezvipi zvakanakira retatrutide?
4.Kuenzanisa Zvikomborero zveRetatrutide uye Tirzepatide
Ndeupi musiyano uripo pakati petirzepatide uye retatrutide?
Musiyano mukuru pakati petirzepatide uye retatrutide uri muchimiro chavo.Tirzepatide inosanganiswa yezvikamu zvitatu zvinoshanda - liraglutide, glucagon-like peptide-1 agonist (GLP-1);analogue ye oxyntomodulin;uye GLP-2 analogue.Retarutide, kune rumwe rutivi, inoumbwa nechinhu chimwe chinoshanda - exenatide, imwe GLP-1 yakanyanyisa mupancreas.Mishonga miviri iyi inoshandiswa kubata chirwere cheshuga chechipiri nekuwedzera kugadzirwa kwe insulin uye kudzikisa mazinga eglucose eropa.Zvisinei, retarutide yakaratidzawo kuderedza kudya zvakanyanya kupfuura tirzepatide chete nekuda kwekuita kwayo pamahomoni anobatanidzwa munzara uye satiety.Saka nekudaro, inogona kushandiswa sechikamu chenzira yakabatanidzwa yekuremedza manejimendi kune vanhu vane chirwere cheshuga vakafuta kana vakafuta.
Ndezvipi zvinobatsira zve tirzepatide?
①Yakavandudzwa glycemic control uye A1C mazinga, zvichitungamira kune hutano hwese huri nani
Tirzepatide, glucagon-like peptide 1 receptor agonist uye GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonist, inzira itsva yekurapa yechirwere cheshuga chechipiri.Yakawanikwa ichinyanya kushanda kupfuura retatrutide mukuvandudza glycemic control uye A1C mazinga.Mumakiriniki ekuedzwa, tirzepatide yakabatanidzwa nekuderera kukuru mumazinga eA1C pamasvondo e12 achienzaniswa neretatrutide (-2.3% vs -1.8%), zvichiita kuti zvive nani hutano hwehutano kune varwere.
②Kuderedza njodzi yezviitiko zvemoyo senge heart attack uye sitiroko
Tirzepatide inopa huwandu hwezvinogona kubatsira kune vanhu vari panjodzi yezviitiko zvemoyo sekurwadziwa kwemoyo uye sitiroko.Ongororo ya2019 yakaburitswa mupepanhau The Lancet yakawana kuti vanhu vanotora tirzepatide vaive nenjodzi yakaderera yezviitiko zvakakomba zvemoyo (MACE) zvichienzaniswa nevaya vanotora retatrutide.Izvi zvaisanganisira kuderedzwa kwe35% muMACE kana ichienzaniswa neretatrutide, iyo yakaratidza hapana mutsauko wakakura mukuita panjodzi dzemoyo.Mukati mekudzidza, vaongorori vakaona kuti varwere vanotora tirzepatide vakawana yakaderera mwero yecoronary artery disease, myocardial infarction, congestive heart failure uye sitiroko kupfuura avo vari muboka retatrutide.Pamusoro pezvo, vatori vechikamu vakatora tirzepatide vakashumawo mazinga akavandudzwa ekudzora shuga yeropa uye kushomeka kwehuremu zvichienzaniswa nevaya vanotora retatrutide.Chekupedzisira, zvakakosha kucherechedza kuti vanhu vanotora tirzepatide havana kungodzivirirwa kubva kuMACE asi zvakare vaive nekudzikira kwemazinga eHbA1c (mucherechedzo wekukuvara kwenguva refu kwechirwere cheshuga) uye huwandu hwemafuta emuviri kana uchienzaniswa nemazinga ekutanga.Pakupedzisira, mhedzisiro iyi inonongedza kugona kwetirzepatide kuderedza zviitiko zvemoyo zvine chekuita nerudzi rwe2 chirwere cheshuga uye kupa mamwe mabhenefiti ane chekuita nekuumbwa kwemuviri.
Kudzika kwehuremu hwemuviri uchienzaniswa neretatrutide, iyo inogona kubatsira kuderedza njodzi yezvirwere zvine chekuita nekufutisa
Tirzepatide ine mabhenefiti akati wandei kana ichienzaniswa neretatrutide, kunyanya kana zvasvika pahuremu hwemuviri.Zvidzidzo zvakawana kuti tirzepatide inogona kukonzera kuderera kwakanyanya kwehuremu hwemuviri pane retatrutide pamusoro penguva refu.Izvi zvinogona kuve zvakakonzerwa nekugona kwayo kukurudzira GLP-1 receptor chiitiko uye kukurudzira satiety.Mukuwedzera, tirzepatide yakawanikwa ichideredza mafuta emudumbu zviri nani pane retatrutide, iyo inogona kubatsira kuderedza njodzi yechirwere cheshuga, chirwere chemwoyo, uye zvimwe zvirwere zvine chokuita nekufutisa.Uyezve, tirzepatide yakaratidzwa kuderedza shuga yeropa zvakanyanya kupfuura retatrutide.Izvi mhedzisiro zvakasanganiswa zvinogona kuvandudza hutano hwakakwana hunoenderana nekufutisa uye metabolic dysfunction.
③Kuwedzera simba mazinga nekuda kwekuvandudzwa kweglucose metabolism
Imwe yemabhenefiti akakosha ekutora tirzepatide kugona kwayo kuwedzera simba mazinga nekuda kwekuvandudzwa kweglucose metabolism.Izvi zvinodaro nekuti GLP1 receptor agonists senge tirzepatide basa nekukurudzira kuburitswa kwe insulin mukupindura kune yakakwirira shuga yeropa.Nekuwedzera kugadzirwa kwe insulini nekuvandudza glucose metabolism, muviri unogona kushandisa glucose yakawanda yehuni uye izvi zvinogona kutungamirira kukuwedzera simba.Mukuwedzera, GLP1 receptor agonists inogonawo kuderedza kudya, zvichiita kuti kuderedzwa kwechikafu chekudya uye kugadzirisa uremu.
Ndezvipi zvakanakira retatrutide?
Retatrutidemushonga unobaiwa kwenguva refu unoshandiswa kurapa chirwere cheshuga cherudzi rwechipiri.Yakatenderwa neUS Food and Drug Administration (FDA) nechinangwa ichi.Zvakanakira retatrutide zvakawanda, zvichiita kuti ive sarudzo inoyevedza pakati pemamwe mishonga yechirwere cheshuga.
Kutanga, retatrutide inoshanda nekukurumidza kana yangobaiwa uye mhedzisiro yayo inogona kunzwika mukati memaawa makumi maviri nemana ekutonga.Izvi zvinoita kuti zvive nekukurumidza kuita kupfuura mamwe majekiseni akareba-anoita setirzepatide, izvo zvinogona kutora kusvika kumavhiki akati wandei zvisati zvaonekwa zvinoonekwa mumazinga eshuga yeropa.
Mukuwedzera, zvidzidzo zvakaratidza kuti retatrutide inoshanda pakuderedza mazinga eA1C kune vanhu vane chirwere cheshuga chechipiri kana inotorwa pamwe chete nekudya uye kuchinja kwekurovedza muviri.Miedzo yemakiriniki yakaratidzawo kuti retatrutide inobatsira kuderedza kutsanya mazinga eglucose uye yakazara glycemic control muvashandisi kana ichienzaniswa ne placebo.Mune zvimwe zviitiko, vanhu vasina kuwana rubatsiro kubva kumuromo chirwere cheshuga vane mhedzisiro yakabudirira neretatrutide therapy.
Chekupedzisira, imwe yemabhenefiti makuru eretatrutide ndeye nyore kutonga maitiro;zvinoda jekiseni rimwe chete pasvondo panzvimbo pemajekiseni akawanda ezuva nezuva semamwe marapirwo mazhinji echirwere cheshuga.Izvi zvinogona kuita kuti kutarisira chirwere chako cheshuga kuve nyore uye kubatsira kuvandudza kutevedza kwemurwere kune chirongwa chekurapa nekufamba kwenguva.
Kuenzanisa Mabhenefiti eRetatrutide uye Tirzepatide
Kana zvasvika pakubudirira, retatrutide yakaratidza kuderedza HbA1c mazinga ne 1.9-2.4%, zvichienzaniswa neTirzepatide iyo inoderedza HbA1c mazinga ne 1.5-2%.Mishonga miviri inewo mhedzisiro yakafanana, sekusvotwa uye musoro.Nekudaro, vamwe vanhu vanogona kuona kuti vanowana mashoma mhedzisiro neRetatrutide pane neTirzepatide nekuda kweiyo yakaderera dosi zvinodiwa.
Panyaya yekuchengeteka, retarutide inowanzotenderwa zvakanaka kana ikashandiswa pazviyero zvinokurudzirwa uye haiwedzeri njodzi yehypoglycemia kana kukonzera uremu sezvinogona kuitwa nemamwe marapirwo echirwere cheshuga.Nekune rimwe divi, Tirzepatide inotakura njodzi yepamusoro yejekiseni saiti maitiro nekuda kwehukuru hwayo.Pamusoro pezvo, kana ikatorwa zvakawandisa inogona kukonzera yakanyanya hypoglycemia uye kuwedzera uremu.
Muchidimbu, zvese zviri zviviri retarutide uye tirzepatide isarudzo dzinoshanda dzekugadzirisa Type 2 chirwere cheshuga asi imwe inogona kuve yakakodzera kune vamwe varwere zvichienderana nezvavanoda.Retarutide inopa kushanda kwakanaka nekushomeka kwemhedzisiro uku zvakare kuve yakachengeteka pane inokurudzirwa madosi;zvisinei, Tirzepatide inogona kupa kuderera kukuru mumazinga eHbA1c asi inogonawo kutakura njodzi yakakura yemigumisiro yakakomba kana ikasashandiswa zvakanaka.Pakupedzisira, zvakakosha kubvunza chiremba wako kuitira kuti usarudze kuti ndeipi nzira yekurapa yakakunakira iwe zvichienderana nemamiriro ako chaiwo uye zvinangwa zvehutano.
Tanga yako tirzepatide uye semaglutide kurapa kuLianFu
Nguva yekutumira: Mar-18-2024